SeaStar Medical Holding Corp
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
ICU$1.90-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(9,246) | $(20,411) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of deferred financing costs | 18 | 102 |
| Change in fair value of convertible notes (issued, converted and outstanding) | — | 6,145 |
| Change in fair value of liability classified warrants (exercised and outstanding) | (32) | 773 |
| Shares issued for the standby equity purchase agreement commitment fee | 298 | — |
| Stock-based compensation | 554 | 675 |
| Change in operating assets and liabilities | ||
| Accounts receivables, net | (109) | (68) |
| Inventory | (83) | — |
| Prepaid expenses | 1,028 | 666 |
| Other assets | 236 | 235 |
| Accounts payable | (1,028) | (858) |
| Accrued expenses | (1,141) | 932 |
| Other liabilities | — | 495 |
| Net cash used in operating activities | (9,505) | (11,314) |
| Cash flows from financing activities | ||
| Proceeds from issuance of convertible notes | — | 979 |
| Payment of convertible notes | — | (700) |
| Proceeds from issuance of shares, net of offering costs | 14,337 | 13,582 |
| Proceeds from exercise warrants | 1,818 | 853 |
| Proceeds of pre-funded warrants | 5,886 | 3,766 |
| Payment of notes payable | (592) | (5,260) |
| Net cash provided by financing activities | 21,449 | 13,220 |
| Net increase in cash | 11,944 | 1,906 |
| Cash, beginning of period | 1,819 | 176 |
| Cash, end of period | $13,763 | $2,082 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $— | $523 |
| Exercise of liability classified warrants | $— | $3,106 |
| Shares issued from conversion of convertible notes | $— | $10,210 |
| Board compensation settled in shares of common stock in-lieu of cash | $— | $210 |
| Issuance of convertible note warrants | $— | $586 |
September 30, 2025
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.